(2S)-4-(苯基甲基)-2-吗啉甲胺 | 186293-55-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2S)-4-(苯基甲基)-2-吗啉甲胺
• 中文别名: (S)-(4-苄基吗啉-2-基)甲胺
• 英文名称: (S)-(4-benzylmorpholin-2-yl)methanamine
• 英文别名: 1-[(2S)-4-benzylmorpholin-2-yl]methanamine；(S)-2-aminomethyl-4-benzylmorpholine；[(2S)-4-benzylmorpholin-2-yl]methanamine
• CAS: 186293-55-0
• 化学式: C₁₂H₁₈N₂O
• 分子量: 206.288
• InChiKey: CKZVBXBEDDAEFE-LBPRGKRZSA-N

物化性质

• 沸点：
  312.3±22.0 °C(Predicted)
• 密度：
  1.076±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2S)-4-(苯基甲基)-2-吗啉甲胺 在 sodium hydroxide 、 聚合甲醛 、 甲酸 作用下， 以 水 为溶剂， 生成 (S)-4-benzyl-2-(N,N-dimethylaminomethyl)morpholine
  参考文献：
  名称：

  Prophylactic or therapeutic agent for diseases attributable to infection with helicobacters

  摘要：

  本发明涉及一种用于预防和治疗由幽门螺杆菌感染引起的疾病的制剂，包括（S）-1-环丙基-1,4-二氢-7-[2-(N,N-二甲基氨甲基)吗啉基]-6-氟-8-甲氧基-4-氧代喹啉-3-羧酸或其药学上可接受的盐。本发明的预防和治疗剂即使在小剂量和短时间内单独使用也有效，几乎没有耐受性和腹泻等问题性副作用，毒性低且能够安全有效地根除细菌。它对于预防和治疗由幽门螺杆菌感染引起的疾病特别有效，包括胃炎、胃溃疡、十二指肠溃疡、恶性淋巴瘤和胃癌。

  公开号：

  US06221864B1
• 作为产物：
  描述：

  4-苄基吗啉-2-甲腈 在 lithium aluminium tetrahydride 、 rac-tartaric acid dibenzoate 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 2.0h， 生成 (2S)-4-(苯基甲基)-2-吗啉甲胺
  参考文献：
  名称：

  Discovery of triazolopyrimidine-based PDE8B inhibitors: Exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes

  摘要：

  PDE8B is a cAMP-specific isoform of the broader class of phosphodiesterases (PDEs). As no selective PDE8B inhibitors had been reported, a high throughput screen was run with the goal of identifying selective tools for exploring the potential therapeutic utility of PDE8B inhibition. Of the numerous hits, one was particularly attractive since it was amenable to rapid deconstruction leading to inhibitors with very high ligand efficiency (LE) and lipophilic ligand efficiency (LLE). These triazolopyrimidines were optimized for potency, selectivity and ADME properties ultimately leading to compound 42. This compound was highly potent and selective with good bioavailability and advanced into pre-clinical development. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.079

文献信息

• [EN] TROPOMYOSIN-RELATED KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES APPARENTÉES À LA TROPOMYOSINE
  申请人：PFIZER

  公开号：WO2015170218A1

  公开（公告）日：2015-11-12

  The present invention relates to compounds of Formula I and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.

  本发明涉及式I化合物及其药用可接受的盐，其中取代基如本文所述，并且在医学上的应用，特别是作为TrkA拮抗剂。
• Morpholin-acetamide derivatives for the treatment of inflammatory diseases
  申请人：——

  公开号：US20040058923A1

  公开（公告）日：2004-03-25

  Compounds of formula (I) wherein: R 1 represents C 1-16 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 2-6 alkynyl-Y 1 —, aryl-Y 1 —, heteroaryl-Y 1 —, aryl-(O) t -aryl-Y 1 —, aryl-(O) t -heteroaryl-Y 1 —, heteroaryl-(O) t -aryl-Y 1 —, heteroaryl-(O) t -heteroaryl-Y 1 —, C 2-6 alkenyl-Y 1 —, aryl-O—Y 1 —, heteroaryl-O—Y 1 —, C 1-16 alkyl-SO 2 —Y 1 —,M—Y 1 —,J 2 -Y 1 —, —CN or C 3-8 cycloalkyl-Y 1 — or C 3-8 cycloalkenyl-Y 1 —, which cycloalkyl or cycloalkenyl may be optionally substituted by one or more hydroxyl or C 1-16 Alkyl groups; R 2 represents hydrogen or C 1-16 alkyl; X represents ethylene or a group of formula CR e R f wherein R e and R f independently represent hydrogen or C 1-14 alkyl or R e and R f may together with the carbon atom to which they are attached form a C 3-8 cycloalkyl group; R 3 and R 4 independently represent hydrogen or C 1-14 alkyl; Z represents a bond, CO, SO 2 , CR 9 R 6 (CH 2 ) n , (CH 2 ) n CR 9 R 6 , CHR 6 (CH 2 ) n O, CHR 6 (CH 2 ) n S, CHR 6 (CH 2 ) n OCO, CHR 6 (CH 2 ) n CO, COCHR 6 (CH 2 ) n or SO 2 CHR 6 (CH 2 ) n ; n represents an integer from 0 to 4; processes for preparing them, formulations containing them and their use in therapy for the treatment of inflammatory diseases. 1

  式(I)的化合物，其中：R1代表C1-16烷基，C2-6烯基，C2-6炔基，C2-6炔基-Y1—，芳基-Y1—，杂环芳基-Y1—，芳基-(O)t-芳基-Y1—，芳基-(O)t-杂环芳基-Y1—，杂环芳基-(O)t-芳基-Y1—，杂环芳基-(O)t-杂环芳基-Y1—，C2-6烯基-Y1—，芳基-O—Y1—，杂环芳基-O—Y1—，C1-16烷基-SO2—Y1—，M—Y1—，J2-Y1—，—CN或C3-8环烷基-Y1—或C3-8环烯基-Y1—，其中环烷基或环烯基可以选择地被一个或多个羟基或C1-16烷基基团取代；R2代表氢或C1-16烷基；X代表乙烯或公式CReRf的基团，其中Re和Rf独立地代表氢或C1-14烷基，或Re和Rf可以与它们连接的碳原子一起形成C3-8环烷基基团；R3和R4独立地代表氢或C1-14烷基；Z代表键，CO，SO2，CR9R6(CH2)n，(CH2)nCR9R6，CHR6(CH2)nO，CHR6(CH2)nS，CHR6(CH2)nOCO，CHR6(CH2)nCO，COCHR6(CH2)n或SO2CHR6(CH2)n；n代表一个从0到4的整数；它们的制备方法，包含它们的配方以及它们在治疗炎症性疾病中的用途。
• [EN] SUBSTITUTED TRIAZOLOPYRIMIDINES AS PDE8 INHIBITORS<br/>[FR] TRIAZOLOPYRIMIDINES SUBSTITUÉES COMME INHIBITEURS DE PDE8
  申请人：PFIZER

  公开号：WO2011058478A1

  公开（公告）日：2011-05-19

  Compounds of Formula (I): wherein R1 , R2, R3, R4, and R5 are as defined herein, are disclosed.

  式(I)的化合物：其中R1，R2，R3，R4和R5如本文所定义，已被披露。
• Process for the preparation of morpholine derivatives and intermediates therefore
  申请人：Hayes Alistair Martin

  公开号：US20050222147A1

  公开（公告）日：2005-10-06

  Processes for the preparation of a compound of formula (IIIA) or a salt thereof are disclosed.

  本发明揭示了制备式（IIIA）化合物或其盐的过程。
• Heterocyclic Compounds, their Preparation and their Use as Antibacterials
  申请人：Caileau Nathalie

  公开号：US20090036433A1

  公开（公告）日：2009-02-05

  Tricyclic nitrogen containing compounds of formula (I) and their use as antibacterials.

  公式（I）中含有三环氮化合物及其作为抗菌剂的用途。